Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CCR4 | P51679 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27123592 | 0.93 | GAA (0.55) | GAALMNAMAPK1ALDH1A1SLC40A1 | |
| SCHEMBL30846193 | 0.93 | GAA (0.55) | GAALMNAMAPK1ALDH1A1SLC40A1 | |
| SCHEMBL27118142 | 0.89 | SLC40A1 (0.41) | LMNAALDH1A1SLC40A1MEN1KMT2A | |
| SCHEMBL30846341 | 0.89 | SLC40A1 (0.41) | LMNAALDH1A1SLC40A1MEN1KMT2A | |
| SCHEMBL27118277 | 0.88 | GAA (0.38) | GAALMNAMAPK1ALDH1A1SLC40A1 | |
| SCHEMBL30846288 | 0.88 | GAA (0.38) | GAALMNAMAPK1ALDH1A1SLC40A1 | |
| SCHEMBL30846276 | 0.88 | SLC40A1 (0.40) | GAALMNAALDH1A1SLC40A1MEN1 | |
| SCHEMBL27118195 | 0.88 | SLC40A1 (0.40) | GAALMNAALDH1A1SLC40A1MEN1 | |
| SCHEMBL30846255 | 0.86 | EIF2AK3 (0.48) | LMNAMAPK1SLC40A1PIK3CA | |
| SCHEMBL27118018 | 0.86 | PTGES2 (0.46) | GAALMNAALDH1A1SLC40A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150365-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044344-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044344-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150365-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL6B | GAA 2769/4885LMNA 2121/4885MAPK1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.